Abstract 19593: Sirtuin-3 is Essential for Glucagon-like Peptide-1-mediated Restoration of Diabetic Cardiomyopathy
Introduction: Sirtuin 3 (SIRT3) is a mitochondrial protein deacetylase and its expression is increased by fasting and exercise in skeletal muscle; however, the impact of anti-diabetic intervention on diabetic myocardium remained uncertain.
Hypothesis: We hypothesized that the anti-diabetic remedy glucagon-like peptide-1 agonist (exendin-4; Ex4) may ameliorate mitochondrial remodeling observed in diabetic cardiomyopathy.
Methods: Type 2 diabetic mice [T2DM; KKAy and dietary diabetes induced by high fat and high sucrose diet (HF/HS), male 14-16 w/o] and age- and gender-matched SIRT3 knockout mice with dietary diabetes (sirHF/HS) diet were allocated into Ex4 (24 nmole/kg/day for 40 days) and vehicle (CON) groups.
Results: T2DM-CON and sirHF/HS-CON exhibited myocardial hypertrophy, increased fibrosis, decreased cardiac capillary density, and defragmented mitochondria, which were reversed by Ex4. Consistently with the changes in mitochondrial morphology, the mitochondrial regulatory proteins mitofusin-1 (Mfn1) and mitofusin-2 (Mfn2) ratio was reduced in T2DM-CON and sirHF/HS-CON, which were ameliorated by Ex4 treatment exclusively to T2DM-CON. T2DM-CON exhibited decrease in cardiac SIRT3 level compared to nondiabetic counterpart, which was ameliorated by Ex4. Interestingly, cardiac remodeling of sirHF/HS-CON remained unchanged by Ex4 treatment, exclusively to cardiac capillary density. T2DM-CON and sirHF/HS-CON exhibited decrease in cardiac cyclic AMP level, which were attenuated by Ex4. The GLP-1 inactive analog (Ex9-39) failed to increase cardiac cyclic AMP concentration in mouse heart. In vitro analysis using cultured cardiomyocytes revealed that increase in intracellular cAMP levels by isoprotelenol (10microM) or 8-bromo-cyclic AMP (10 microM) enhanced SIRT3 mRNA, which was reversed by protein kinase A (PKA) inhibition.
Conclusions: Our results indicate that Ex4 reversed abnormal suppression of SIRT3 in mitochondria of diabetic heart via restoration of cardiac cAMP.
Author Disclosures: A. Monji: None. Y.K. Bando: Research Grant; Modest; MSD,. Research Grant; Significant; AstraZeneca. Speakers Bureau; Significant; MSD, Takeda, AstraZeneca. H. Kawase: None. H. Nishimura: None. M. Aoyama: None. T. Mitsui: None. T. Murohara: Research Grant; Modest; Astellas, Daiichi Sankyo, Dainippon Sumitomo, Kowa, MSD, Mitsubishi Tanabe, Nippon Boehringer Ingelheim. Honoraria; Modest; Bayer, Daiichi Sankyo, Dainippon Sumitomo, Kowa, MSD, Mitsubishi Tanabe, Nippon Boehringer Ingelheim, Novartis, Pfizer Japan, SanofiAventis, and Takeda..
- © 2015 by American Heart Association, Inc.